The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients

Journal of the Pakistan Medical Association

Volumn 62, Issue 9, 2012, Pages 871-875

  Golmohammadi, Rahim ^a   Pejhan, Akbar ^a  

^a SABZEVAR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Ki67 marker; P53 protein; Prognosis

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN STABILITY; SURVIVAL;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IRAN; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN STABILITY; SEX FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865859730     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk.Cancer Epidemiol Biomarkers Prev 1999; 10: 843-54.
2. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009; 20: 556-63.
3. McPherson K, Steel CM, Dixon JM. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000; 321: 624-8.
4. Hofseth LJ, Hussain SP, Harris CC. P53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177-81.
5. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 1992; 25: 31-40.
6. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-22.
7. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA Lancet. Ki67 in breast cancer: prognostic and predictive potential. Oncol 2010; 11: 174-83.
8. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 2005; 16: 1723-39.
9. Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, Fernö M. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. South Sweden Breast Cancer Group Mod Pathol 2010; 23: 251-9.
10. Taneja P, Maglic D, Kai F, Zhu S, Kendig RD, Fry EA, et al. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clin Med Insights Oncol 2010; 4:15-34.
11. Sloane JP, Anderson TJ, Blamey RW, Brown CL, Chamberlain J, Coyne J, et al. Pathology reporting in breast cancer screening. 2nd ed. National coordinating group for breast screening pathology. NHSBSP Publication No. 3, 1995; pp 19-21.
12. Breast cancer.org Website. Stages of breast cancer. (Online) (Cited 2008 Sept 2). Available from URL: http://www.breastcancer.org/dia_pict_staging.html.
13. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005; 18: 374-81.
14. Tan PH, Chuah KL, Chiang G, Wong CY, Dong F, Bay BH. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast. Oncol Rep 2002; 9: 1081-6.
15. Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H. P53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 2006; 8: R48.
16. Sangrajrang S, Arpornwirat W, Cheirsilpa A, Thisuphakorn P, Kalalak A, Sornprom A, et al. Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev 2003; 27: 182-6.
17. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, et al. P53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993; 53: 4665-9.
18. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995; 71: 146-9.
19. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005; 18: 374-81.
20. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) versus invasive breast cancer alone. Anticancer Res 2005; 25: 1719-23.
21. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Fernö M; South Sweden Breast Cancer Group. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001; 37: 1514-22.
22. Hu SW, Chuang JH, Tsai KB. Immunohistochemical expression in male breast cancer: two case reports. Kaohsiung J Med Sci 2006; 22: 235-42.
23. Andreopoulou E, Hortobagyi GN. Prognostic Factors in Metastatic Breast Cancer: Successes and Challenges Toward Individualized Therapy. J Clin Oncol 2008; 26: 3660-2.